Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT (RAFHAS)
A Phase I Study Evaluating The Use Of Rft5-Dga To Deplete Alloreactive Cells For Patients With Fanconi Anemia After Haploidentical Stem Cell Transplantation
Sponsor: Baylor College of Medicine
Terminated
Poor accrual
Other terminated trials from Baylor College of Medicine
Listed as NCT00586274, this PHASE1 trial focuses on FANCONI ANEMIA and remains terminated or withdrawn. Sponsored by Baylor College of Medicine, it has been updated 6 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Mar 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Baylor College of Medicine
- Center for Cell and Gene Therapy, Baylor College of Medicine
- University of Texas, Southwestern Medical Center at Dallas
For direct contact, visit the study record on ClinicalTrials.gov .